Who's Promised What: A Guide To Pharma Drug Pricing Pledges
Have pharma companies responded sufficiently to President Trump's call for “massive” price reductions?
You may also be interested in...
Advocates for drug pricing reform don’t have much in the way of price increases to complain about at the moment – but they argue that the price hikes they are seeing suggest a growing confidence among manufacturers that the threat of drug pricing reform is subsiding.
The idea could help quiet growing criticism over system gaming and high drug prices.
Presiding over his last earnings call as the CEO of Pfizer, Ian Read was pressed about the company's drug pricing strategy for 2019 amid push back from the Trump Administration.